<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596648</url>
  </required_header>
  <id_info>
    <org_study_id>XL184-202</org_study_id>
    <nct_id>NCT00596648</nct_id>
  </id_info>
  <brief_title>A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1b/2 Study of XL184 With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exelixis</source>
  <brief_summary>
    <textblock>
      In Phase 1 of this study, the purpose is to evaluate the safety, tolerability, and highest&#xD;
      safe dose of the multiple receptor tyrosine kinase inhibitor (including VEGFR2, MET, and RET)&#xD;
      XL184 in combination with the EGFR inhibitor erlotinib administered to adults with&#xD;
      Non-Small-Cell Lung Cancer (NSCLC). In Phase 2 of this study, the purpose is to evaluate the&#xD;
      objective response rate of daily oral administration of XL184 with or without erlotinib in&#xD;
      subjects with NSCLC who have progressed after responding to treatment with erlotinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In Phase 1 of the study: evaluate safety, tolerability, and maximum tolerated dose of daily oral administration of XL184 in combination with erlotinib to subjects with NSCLC</measure>
    <time_frame>Assessed at each visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 1 of the study, to evaluate pharmacodynamic effects of XL184 administration in combination with erlotinib</measure>
    <time_frame>Assessed at periodic visits</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 1 of the study, to characterize pharmacokinetic parameters of single agent erlotinib, and of XL184 in combination with erlotinib</measure>
    <time_frame>Assessed at periodic visits (approx. every 8 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 2 of the study, to estimate the objective response rate of XL184 with or without erlotinib in adults with NSCLC who have progressed after responding to erlotinib</measure>
    <time_frame>Assessed approx. every 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Phase 2 of the study, to assess pharmacodynamic effects of XL184 administration either alone or with erlotinib</measure>
    <time_frame>Assessed at periodic visits</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Phase 1 and 2 of the study, to evaluate the long-term safety and tolerability of XL184 administered either alone or in combination with erlotinib</measure>
    <time_frame>Assessed at periodic visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Phase 2 of the study, to assess progression-free survival, duration of response, and overall survival following treatment with XL184 either alone or in combination with erlotinib</measure>
    <time_frame>Assessed at periodic visits (approx. every 8 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Phase 2 of the study, to characterize pharmacokinetic parameters of XL184 as a single agent and XL184 in combination with erlotinib in subjects with NSCLC</measure>
    <time_frame>Assessed at periodic visits (every 8 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Phase 1 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of XL184 + erlotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XL184 + erlotinib (dose determined from Phase 1 portion of study)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XL184 administered as a single agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XL184</intervention_name>
    <description>Capsules administered orally daily</description>
    <arm_group_label>Phase 1 Arm</arm_group_label>
    <arm_group_label>Phase 2 Arm 1</arm_group_label>
    <arm_group_label>Phase 2 Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Tablets administered orally daily.</description>
    <arm_group_label>Phase 1 Arm</arm_group_label>
    <arm_group_label>Phase 2 Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed NSCLC and Stage 3b or 4 NSCLC (Phase 1 only), Stage 3b or 4&#xD;
             NSCLC (Phase 2 only)&#xD;
&#xD;
          -  Documented progressive disease following a prior RECIST response to monotherapy with&#xD;
             erlotinib OR documented progressive disease following stable disease of at least 6&#xD;
             months on monotherapy with erlotinib (Phase 2 only)&#xD;
&#xD;
          -  Must have tolerated erlotinib at the maximal dose that will be administered in Phase 2&#xD;
             only (or at a higher dose) for a minimum of 6 weeks&#xD;
&#xD;
          -  Measurable disease per RECIST (Phase 2 only)&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Adequate organ and marrow function&#xD;
&#xD;
          -  Sexually active subjects must agree to use medically accepted methods of contraception&#xD;
             during the course of the study and for 3 months following discontinuation of study&#xD;
             treatment (excluding women who are not of child bearing potential and men who have&#xD;
             been sterilized).&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative pregnancy test at&#xD;
             enrollment&#xD;
&#xD;
          -  No other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ&#xD;
             of the cervix or malignancy diagnosed ≥ 2 years previously, and currently with no&#xD;
             evidence of disease).&#xD;
&#xD;
          -  Capable of understanding and complying with the protocol, and written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received anti-cancer treatment within 4 weeks, except erlotinib, prior to first dose&#xD;
             (Phase 1 only)&#xD;
&#xD;
          -  In Phase 2 only: the subject has received:&#xD;
&#xD;
               -  Small molecule inhibitors of VEGFR2/KDR OR&#xD;
&#xD;
               -  An investigational anti-cancer agent within 4 weeks of the first dose of study&#xD;
                  drug OR&#xD;
&#xD;
               -  An investigational agent that targets EGF or EGFR at any time OR&#xD;
&#xD;
               -  An approved agent that targets EGF or EGFR (with the exception of erlotinib and&#xD;
                  gefitinib) at any time unless approved by Exelixis OR&#xD;
&#xD;
               -  Anti-cancer therapy within 4 weeks (with the exception of gefitinib and&#xD;
                  erlotinib) of the first dose of study drug OR&#xD;
&#xD;
               -  Prior therapy with a c-Met inhibitor&#xD;
&#xD;
          -  Not recovered to NCI CTCAE v.3 Grade ≤1 from clinically significant adverse events due&#xD;
             to antineoplastic agents, investigational drugs, or other medications administered&#xD;
             prior to study enrollment&#xD;
&#xD;
          -  Symptomatic or uncontrolled brain metastases requiring current treatment, including&#xD;
             steroids and anticonvulsants&#xD;
&#xD;
          -  History of significant hematemesis or recent history of hemoptysis&#xD;
&#xD;
          -  Presence of cavitation, central lesion, or lesion abutting a major blood vessel&#xD;
&#xD;
          -  Intercurrent illness such as hypertension or cardiac arrhythmias or recent history of&#xD;
             significant disease such as congestive heart failure&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Active bacterial or viral infection requiring systemic treatment&#xD;
&#xD;
          -  Allergy or hypersensitivity to components of either the XL184 or erlotinib&#xD;
             formulations&#xD;
&#xD;
          -  Incapable of understanding and complying with the protocol or unable to provide&#xD;
             informed consent&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis or interstitial lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Katmai Oncology Group</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University/Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Institute</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington/ Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Non-Small-Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

